MM Id Vaccine Patient Characteristics
| Patient (UPN) . | Sex/Age . | Id Isotype . | Prior Therapy (no. of cycles) . | Pre-PBSCT Conditioning . | Post-PBSCT Response . |
|---|---|---|---|---|---|
| 1 (1172) | M/37 | IgAλ | VAD (×5) | FTBI + MEL | CR |
| 2 (1243) | M/44 | IgG1κ | VMCP (×1), VAD (×6), VP16 (×2), PSC-VAD (×5) | BCNU + MEL | PR |
| 3 (1289) | M/42 | IgAκ | VAD (×6) | FTBI + MEL | PR |
| 4 (1353) | M/54 | IgG1κ | VAD (×4) | FTBI + MEL | PR |
| 5 (1397) | M/59 | IgG1κ | MP (×12), VAD (×6) | FTBI + MEL | PR |
| 6 (1396) | F/50 | IgG1κ | VAD (×4), PSC-VAD (×4), MEL 140 (×1) | FTBI + MEL | SD |
| 7 (1445) | M/68 | IgG1κ | MP (×7), VAD (×4) | BCNU + MEL | PR |
| 8 (1441) | F/50 | IgAκ | CVP (×23), BMVP (×13), VAD (×2) | FTBI + MEL | PR |
| 9 (1457) | M/53 | IgG3κ | MP (×12), VAD (×4) | BCNU + MEL | CR |
| 10 (1483) | M/41 | IgG1κ | VAD (×4) | FTBI + MEL | PR |
| 11 (1504) | M/51 | IgG4κ | VAD (×6) | FTBI + MEL | PR |
| 12 (1521) | M/59 | IgG4λ | VAD (×6), PSC-VAD (×2) | FTBI + MEL | PR |
| Patient (UPN) . | Sex/Age . | Id Isotype . | Prior Therapy (no. of cycles) . | Pre-PBSCT Conditioning . | Post-PBSCT Response . |
|---|---|---|---|---|---|
| 1 (1172) | M/37 | IgAλ | VAD (×5) | FTBI + MEL | CR |
| 2 (1243) | M/44 | IgG1κ | VMCP (×1), VAD (×6), VP16 (×2), PSC-VAD (×5) | BCNU + MEL | PR |
| 3 (1289) | M/42 | IgAκ | VAD (×6) | FTBI + MEL | PR |
| 4 (1353) | M/54 | IgG1κ | VAD (×4) | FTBI + MEL | PR |
| 5 (1397) | M/59 | IgG1κ | MP (×12), VAD (×6) | FTBI + MEL | PR |
| 6 (1396) | F/50 | IgG1κ | VAD (×4), PSC-VAD (×4), MEL 140 (×1) | FTBI + MEL | SD |
| 7 (1445) | M/68 | IgG1κ | MP (×7), VAD (×4) | BCNU + MEL | PR |
| 8 (1441) | F/50 | IgAκ | CVP (×23), BMVP (×13), VAD (×2) | FTBI + MEL | PR |
| 9 (1457) | M/53 | IgG3κ | MP (×12), VAD (×4) | BCNU + MEL | CR |
| 10 (1483) | M/41 | IgG1κ | VAD (×4) | FTBI + MEL | PR |
| 11 (1504) | M/51 | IgG4κ | VAD (×6) | FTBI + MEL | PR |
| 12 (1521) | M/59 | IgG4λ | VAD (×6), PSC-VAD (×2) | FTBI + MEL | PR |
Abbreviations: UPN: unique patient number; VAD: vincristine, adriamycin, dexamethasone; VMCP: vincristine, melphalan, cyclophosphamide, prednisone; PSC-VAD: PSC 833, vincristine, adriamycin, dexamethasone; MP: melphalan, prednisone; MEL 140: melphalan at 140 mg/m2; CVP: cyclophosphamide, vincristine, prednisone; BMVP: BCNU, melphalan, vincristine, prednisone; SD: stable disease.